Arpeggio Bio
YC S19Arpeggio Bio develops drugs targeting transcription factors using AI…
Boulder, CO, USAFounded 201920 employeeswww.arpeggiobio.com
Team
20
Founded
2019
About
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
No open roles at this time.
Similar Healthcare startups
AT
Altay Therapeutics
Altay develops disease-modifying therapies targeting transcription…
AI-powered Drug DiscoveryBiotechTherapeutics
Open Jobs —
Team 6
Founded 2020
Sequence Bio
Discovering the true signals of disease to power life-changing drugs.
GenomicsTherapeuticsDrug discovery
Open Jobs —
Team 52
Founded 2019
Talus Bio
Discovering drugs that target the DNA regulome
BiotechGenomicsDrug discovery
Open Jobs —
Team 16
Founded 2021
Asher Bio
We build better immunotherapies
Biotech
Open Jobs —
Team 3
Founded 2019